Evidence map›Paper›PMID 31921759›Full record

ArticleFrontiers in chemistry2019

Novel Quinoline Compound Derivatives of NSC23925 as Potent Reversal Agents Against P-Glycoprotein-Mediated Multidrug Resistance.

Xingping Quan, Hongzhi Du, Jingjing Xu, Xiaoying Hou, Xiaofeng Gong, Yao Wu, Yuqi Zhou, Jingwei Jiang, Ligong Lu, Shengtao Yuan and 3 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in chemistry, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.4field-weighted citation impact, top 33% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 13 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 5 institutions in 1 country.

Xingping QuanJiangsu Key Laboratory of Drug Screening, China Pharmaceutical University, Nanjing, China.
Hongzhi DuSchool of Pharmacy, Hubei University of Chinese Medicine, Wuhan, China.
Jingjing XuHenan Key Laboratory of Organic Functional Molecules and Drug Innovation, School of Chemistry and Chemical Engineering, Henan Normal University, Xinxiang, China.
Xiaoying HouJiangsu Key Laboratory of Drug Screening, China Pharmaceutical University, Nanjing, China.
Xiaofeng GongJiangsu Key Laboratory of Drug Screening, China Pharmaceutical University, Nanjing, China.
Yao WuJiangsu Key Laboratory of Drug Screening, China Pharmaceutical University, Nanjing, China.
Yuqi ZhouJiangsu Key Laboratory of Drug Screening, China Pharmaceutical University, Nanjing, China.
Jingwei JiangJiangsu Key Laboratory of Drug Screening, China Pharmaceutical University, Nanjing, China.
Ligong LuZhuhai Interventional Medical Center, Zhuhai Precision Medical Center, Zhuhai People's Hospital, Zhuhai Hospital Affiliated with Jinan University, Zhuhai, China.
Shengtao YuanJiangsu Key Laboratory of Drug Screening, China Pharmaceutical University, Nanjing, China.
Xiangyu YangZhuhai Interventional Medical Center, Zhuhai Precision Medical Center, Zhuhai People's Hospital, Zhuhai Hospital Affiliated with Jinan University, Zhuhai, China.
Lei ShiHenan Key Laboratory of Organic Functional Molecules and Drug Innovation, School of Chemistry and Chemical Engineering, Henan Normal University, Xinxiang, China.
Li SunJiangsu Key Laboratory of Drug Screening, China Pharmaceutical University, Nanjing, China.
China Pharmaceutical University · CNHenan Normal University · CNHubei University of Chinese Medicine · CNJinan University · CNZhuhai People's Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Multidrug resistance is a serious problem and a common cause of cancer treatment failure, leading to patient death. Although numerous reversal resistance inhibitors have been evaluated in preclinical or clinical trials, efficient and low-toxicity reversal agents have not been identified. In this study, a series of novel quinoline compound derivatives from NSC23925 were designed to inhibit P-glycoprotein (P-gp). Among them, YS-7a showed a stronger inhibitory effect against P-gp than verapamil, as a positive control, when co-incubated with chemotherapy drugs at minimally cytotoxic concentrations. YS-7a suppressed the P-gp transport function without affecting the expression of P-gp but stimulated the ATPase activity of P-gp in a dose-dependent manner. Next, molecular docking was used to predict the six most probable binding sites, namely, SER270, VAL273, VAL274, ILE354, VAL357, and PHE390. Moreover, YS-7a had no effect on cytochrome P450 3A4 activity and showed little toxicity to normal cells. In addition, combined treatment of YS-7a with vincristine showed a better inhibitory effect than the positive control verapamil

Indexed as

molecular dockingmultidrug resistance (MDR)P-glycoprotein (P-gp)quinolinereversal cancer resistance

Identifiers

PMID31921759
PMCPMC6931887
OpenAlexW2996141051

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.